Notice of Pre-Application Webinar for RFA-CA-22-015, Cancer Control Research in Persistent Poverty Areas (U54 Clinical Trial Optional)
Notice Number:
NOT-CA-22-067

Key Dates

Release Date:

March 30, 2022

Related Announcements

RFA-CA-22-015 - Cancer Control Research in Persistent Poverty Areas (U54 Clinical Trial Optional)

Issued by

National Cancer Institute (NCI)

Purpose

The National Cancer Institute (NCI) will hold a pre-application webinar on April 15, 2022, from 12:00 PM to 1:00 PM Eastern Time for the Funding Opportunity Announcement (FOA) RFA-CA-22-015 "Cancer Control Research in Persistent Poverty Areas (U54 Clinical Trial Optional)".

NCI staff members involved in the FOA will provide orientation and assistance to potential applicants by explaining the goals, objectives, and requirements of the FOA, and answer questions from webinar attendees. Prospective applicantsare encouraged tosubmit their questions or commentsto Drs. Shobha Srinivasan ([email protected]) and Amy Kennedy ([email protected]) in advance of the webinar by April 11, 2022. Please include "Pre-application webinar for Persistent Poverty RFA: question/comment submission” in the subject line of the email for all question/comment submissions. Attendees will also be able to submit questions during the webinar, however, questions submitted early will be answered first.

Registration for the webinar is required.

To join the Webinar, pre-registration is required through Webex at: https://cbiit.webex.com/cbiit/j.php?RGID=re4f61d6a162cacab32ee9d422dae7349

Specific Webinar information including the webinar link will be provided upon registration.

Participation in this webinar is not required for the submission of an application in response to RFA-CA-22-015, though interested investigators are encouraged to attend.

Inquiries

Please direct all inquiries to:

Shobha Srinivasan, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6938
Email: [email protected]

Amy Kennedy, Ph.D., M.P.H.
National Cancer Institute (NCI)
Telephone: 240-781-3335
Email: [email protected]